Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Siah2 control of T-regulatory cells limits anti-tumor immunity

ABSTRACT: The NanoString analysis of 784 genes expressed by 24 immune cell types in the melanoma cell at 11 days after injection were performed. The Nanostring analysis uncovered marked difference in key immune regulatory networks associated with T, DC, NC and macrophage function

ORGANISM(S): Mus musculus

PROVIDER: GSE134328 | GEO | 2019/07/17

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

NanoString analysis of immune genes in the tumor at day 10 after injection into WT and Rnf5-/- mice

Project description:The NanoString analysis of 770 genes expressed by 24 immune cell types in the tumors at 10 days after injection were performed. The Nanostring analysis uncovered marked difference in key immune regulatory networks associated with T, DC, NC and macrophage function

2019-03-04 | GSE127753 | GEO

Siah2 control of T-regulatory cells limits anti-tumor immunity

Project description:Understanding mechanisms underlying anti-tumor immunity is pivotal for improving immune-based cancer therapies. Here we demonstrate that growth of inoculated BRAF-mutant melanoma cells was inhibited, up to complete loss, in Siah2-/- mice.

2019-11-27 | GSE134814 | GEO

Siah2 control of T-regulatory cells limits anti-tumor immunity.

Project description: Not available

| S-EPMC6946684 | biostudies-literature

Gene expression profile of Leishmania major infected THP1 cell lines

Project description:Nanostring nCounter gene expression analysis on L. major infected wild type versus knockout THP1 cells was performed based on 784 genes with nCounter PanCancer Immune Profiling CS Kit (no MK).

2022-10-24 | GSE211590 | GEO

Siah2 control of T-regulatory cells limits anti-tumor immunity

Project description:Siah2 control of T-regulatory cells limits anti-tumor immunity

| PRJNA554787 | ENA

Siah2 control of T-regulatory cells limits anti-tumor immunity

Project description:Siah2 control of T-regulatory cells limits anti-tumor immunity

| PRJNA556492 | ENA

Interleukin-35 Limits Anti-Tumor Immunity.

Project description: Not available

| S-EPMC4758699 | biostudies-literature

B cell-derived GABA elicits IL-10+ macrophages and limits anti-tumor immunity

Project description:Small, soluble metabolites are not only essential intermediates in intracellular biochemical processes, but can also influence neighboring cells when released into the extracellular milieu. Here, we identify the metabolite and neurotransmitter GABA as a candidate signaling molecule synthesized and secreted by activated B cells and plasma cells. We show that B cell-derived GABA promotes monocyte differentiation into anti-inflammatory macrophages which secrete IL-10 and inhibit CD8+ T cell killer function. In mice, B cell deficiency or B cell-specific inactivation of the GABA generating enzyme GAD67 enhances anti-tumor responses. Our study reveals that in addition to cytokines and membrane proteins, small metabolites derived from B lineage cells have immunoregulatory functions, which may be pharmaceutical targets allowing fine-tuning of immune responses.

2021-11-15 | PXD028403 | Pride

MARCH1 regulates anti-malarial immunity through interferon signaling and T cell activation

Project description:Malaria infection induces complex and diverse immune responses, including impairment of dendritic cell (DC) function and immune suppression that may contribute to the low vaccination antibody titers to some antigens in endemic populations. To elucidate the mechanisms underlying host-parasite interaction, we performed a genetic screen during early Plasmodium yoelii infection and identified a large number of interacting host and parasite genes/loci after trans-species expression quantitative trait loci (Ts-eQTL) analysis. We next investigated a host E3 ubiquitin ligase gene (march1) that was clustered with interferon stimulated genes. March1 can inhibit MAVS/STING induced IFN-I signaling and reverse inhibition of viral replication mediated by MAVS in vitro. However, in malaria-infected hosts, deficiency of march1 activates IFN signaling inhibitors such as SOCS1, SOCS3, and TRIM24, leading to reduced early (24h) serum IFN-I levels. Increased CD86+ DC populations and elevated levels of IFN-? and IL-10 produced by T cells day 4 post infection protect infected march1-/- mice. Malaria lysate stimulate MACRH1 expression, which reduces CD86+ DC cells and impairs T cell activation. This study reveals previous unknown functions of MARCH1 in innate response to malaria infections and provides potential avenues for activating anti-malaria immunity and enhancing vaccine efficacy.

2020-09-11 | GSE119944 | GEO

Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity

Project description:Tumor-infiltrating antigen-presenting cells, such as dendritic cells (DC), have the capacity to shape anti-tumor T cell responses. While tremendous progress has been made in unraveling the role of Batf3-driven DC1 in the anti-tumor immune response, the contributions of other tumor-infiltrating DC subsets remain poorly understood. Furthermore, tumor-infiltrating DC exist in a range of functional states with differential impacts on anti-tumor immunity. In this study, we sought to identify and characterize the functionally relevant DC states associated with a productive anti-tumor T cell response. By comparing the DC infiltrate of spontaneously regressing tumors and progressing tumors, we identified a novel activation state of CD11b+ conventional DC in tumors, which expressed an interferon-stimulated gene signature (‘ISG+ DC’). ISG+ DC were activated by type-I-interferon-induced signaling and could generate protective CD8+ T cell responses by cross-dressing with tumor-derived peptide-MHC complexes. Stimulatory ISG+ DC induced by exogenous IFNβ addition drove robust anti-tumor T cell responses in poorly immunogenic tumors even in the absence of DC1.

2022-01-13 | GSE181938 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data